Literature DB >> 26005000

The multiple myeloma bone eco-system and its relation to oncogenesis.

R Bataille1.   

Abstract

Pure lytic bone lesions are the hallmark of myeloma (MM). MM is the only hematological malignancy associated with lytic bone lesions and the mechanisms of bone destruction are well documented both at the cellular and molecular levels. An uncoupling bone process characterizes MM, with stimulation of bone resorption and inhibition of bone formation. The capacity of MM cells to directly or indirectly inhibit bone formation is specific of MM, although many carcinomas have the capacity to stimulate bone resorption, directly or indirectly in a similar way to MM. Few MM do not develop bone lesions, while true sclerotic MM remain exceptional. Inhibition of bone formation is the major event explaining the transition from MGUS to overt MM. It is now well documented that bone cells regulate MM cell growth, osteoclast stimulating MM cell growth and osteoblasts inhibiting it. Progression of MM from MGUS is characterized by the selection of MM clones able to inhibit osteoblasts, favoring tumor growth. These data underline the interest of new treatments able to regenerate bone.
Copyright © 2015 Elsevier Masson SAS. All rights reserved.

Entities:  

Keywords:  Bone disease; Bone formation; Bone resorption; Formation osseuse; Maladie osseuse; Multiple myeloma; Myélome multiple; Résorption osseuse

Mesh:

Substances:

Year:  2015        PMID: 26005000     DOI: 10.1016/j.morpho.2015.03.002

Source DB:  PubMed          Journal:  Morphologie        ISSN: 1286-0115


  2 in total

1.  Expression and correlation of IL-2, IL-10 and TNF-α in patients with multiple myeloma-infected herpes zoster treated by bortezomib-containing regimen.

Authors:  Kang Liu; Yafei Yin; Xinfu Zhou; Kaibo Zhu; Zimian Luo
Journal:  Am J Transl Res       Date:  2021-12-15       Impact factor: 4.060

2.  Multiple Myeloma Exemplifies a Model of Cancer Based on Tissue Disruption as the Initiator Event.

Authors:  Jean-Pascal Capp; Régis Bataille
Journal:  Front Oncol       Date:  2018-09-10       Impact factor: 6.244

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.